RA Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

RA Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-292,108	Closed	-$5.05M	–	29
2016 Q3	$5.05M	Sell	292,108 -141,165	-33%	-$4.56M	0.52%	25
2016 Q2	$13.6M	Hold	433,273	–	–	1.89%	13
2016 Q1	$11.5M	Hold	433,273	–	–	1.47%	23
2015 Q4	$19M	Buy	433,273 +171,429	+65%	+$7.72M	1.88%	20
2015 Q3	$11.1M	Buy	261,844 +43,859	+20%	+$2.31M	1.59%	22
2015 Q2	$9.98M	Buy	+217,985	New	+$9.99M	1%	30

Other funds holding ARCT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

RA Capital Management's ARCT Position: Q4 2016 in Review

RA Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2016, closing a stake of 292,108 shares — an estimated $5.05M sold.

RA Capital Management first reported a position in ARCT in Q2 2015 and held it in 6 quarters. The position peaked at $19M in Q4 2015. 42 funds tracked by Wall St. Rank hold ARCT as of Q4 2016.

RA Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2016 after selling out during the quarter.
RA Capital Management sold 292,108 Arcturus Therapeutics shares in Q4 2016, an estimated $5.05M.
RA Capital Management first reported a position in Arcturus Therapeutics in Q2 2015 and held it in 6 quarters.
RA Capital Management's Arcturus Therapeutics position peaked at $19M in Q4 2015.
42 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2016.

Based on RA Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.